单宇,张晓剑,朱立帆
SHAN Yu,ZHANG Xiaojian,ZHU Lifan

• 1:苏州市吴江区第一人民医院&南通大学附属吴江医院骨科

摘要(Abstract)：

目的:观察唑来膦酸治疗绝经后骨质疏松症妇女的疗效。方法:选择70例绝经后骨质疏松症患者,根据年龄分为51~60岁组(15例)、61~70岁组(35例)和71~83岁组(20例),采用唑来膦酸静脉滴注治疗,1次/年;采用双能X线仪测定治疗前及治疗后1年患者的腰椎(L2~L4)和股骨颈骨密度(BMD)值,并进行骨痛VAS评分和生活质量ECOS-16评分,观察患者治疗后的不良反应。结果:与治疗前比较,治疗1年后3个年龄组骨质疏松症患者的腰椎(L2~L4)和股骨颈BMD增加,疼痛、身体机能、对疾病的恐惧及心理机能方面的ECOS-16评分均下降,差异有统计学意义(P<0.05);治疗后VAS评分显示,显效29例,有效32例,疼痛缓解总有效率为87.1%;发热为最常见的不良反应。结论:唑来膦酸治疗绝经后骨质疏松症能显著改善患者骨量、减轻患者的疼痛、改善患者生活质量,安全性较好。
Objective: To observe the efficacy of zoledronic acid in the treatment of postmenopausal women with osteoporosis. Methods: 70 patients with postmenopausal osteoporosis were divided into 51~ 60 years old group( 15 cases),61 ~ 70 years old group( 35 cases) and 71-83 year old group( 20 cases),using zoledronic acid intravenous drip treatment,1 time per year. The lumbar( L2 ~ L4) and femoral neck bone mineral density( BMD) was measured by dual energy X ray before and 1 year after treatment. The bone pain VAS score and quality of life ECOS-16 score were used to observe the adverse reactions after treatment. Results: Compared with before treatment,the lumbar( L2 ~ L4) and femoral neck BMD increased in 3 age groups after 1 year treatment. The ECOS-16 scores of pain,body function,fear of disease and psychological function were all decreased,and the differences were statistically significant( P < 0. 05). After treatment,the VAS score showed that 29 cases showed significant effect and 32 cases showed effective,the total effective rate of pain relief was 87. 1%. Fever was the most common adverse reaction. Conclusion: Zoledronic acid can significantly improve bone mass,relieve pain and improve the quality of life of patients with postmenopausal osteoporosis.

关键词(KeyWords)： 唑来膦酸;绝经期;骨密度;骨质疏松症;疗效
zoledronic acid;menopause;bone density;osteoporosis;efficacy analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 单宇,张晓剑,朱立帆
SHAN Yu,ZHANG Xiaojian,ZHU Lifan

DOI: 10.19367/j.cnki.1000-2707.2018.07.026

参考文献(References)：

• [1]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
• [2]NANCOLLAS G H,TANG R,PHIPPS R J,et al.Novel insights into actions of bisphosphonates on bone:Differences in interactions with hydroxyapatite[J].Bone,2006,38(5):617-627.
• [3]MCCLUNG M,RECKER R,MILLERR P,et al.Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate[J].Bone,2007,41(1):122.
• [4]贾秀娟,贾黎,钟丽娜,等.高龄老年骨质疏松症患者应用唑来膦酸注射液的安全性及疗效初步分析[J].中国骨质疏松杂志,2013,10:1080-1083.
• [5]BADIA X,DEZ-PREZ A,LAHOZ R,et al.The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis[J].Health and Quality of Life Outcomes,2004,2(1):41.
• [6]张悦,李兴.经皮椎体成形术联合后凸成形术治疗绝经期骨质疏松性椎体压缩骨折的疗效[J].贵阳医学院学报,2015,40(12):1381-1383.
• [7]邵付印,寇发仓,甘宗东,等.降钙素联合骨肽治疗老年女性骨质疏松症的疗效[J].贵州医科大学学报,2016,41(8):977-979.
• [8]郑骄阳,张兰予,邹俊杰,等.唑来膦酸治疗绝经后骨质疏松症的临床研究[J].中国骨质疏松杂志,2011,17(4):344-346.
• [9]VAN K C.Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809.
• [10]孙敬华,徐晓峰,迟晓飞,等.连续注射唑来膦酸两年治疗绝经后骨质疏松疗效观察[J].中国骨质疏松杂志,2013,19(6):619-621.
• [11]SAAG K,LINDSAY R,KRIEGMAN A,et al.A single mledrome acid infusion reduces bone resorption markers more rapidly than weekly oral alendrenate in postmenopausal women with low bone mineral density[J].Bone,2007,40:1238-1243.
• [12]REID I R,GAMBLE G D,MESENBRINK P,et al.Characterization of and risk factors for the acute-phase response after zoledronic acid[J].Journal of Clinical Endocrinology&Metabolism,2011,95(9):4380-4387.
• [13]李敬会,蔡莉莉,李德梅.唑来膦酸治疗老年骨质疏松症临床分析[J].实用老年医学,2013,(9):777-778.
• [14]王霞.唑来膦酸治疗骨质疏松症24例临床分析[J].上海医药,2013(21):24-25.

文章评论(Comment)：